Amgen Inc. announced on Monday that it would acquire Horizon Therapeutics Plc for $26.4 billion, following earlier speculation on Sunday that hinted at a takeover, after rival bidder Sanofi SA dropped out.
Following the deal, Horizon Therapeutics Plc's value increased to $28.3 billion and gives Amgen Inc. access to several drugs such as Tepezza, a groundbreaking treatment for thyroid eye disease.
The official press release stated that the deal will be effective in early 2023, subject to regulatory approvals.